Spots Global Cancer Trial Database for A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

Official Title: A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

Study ID: NCT01080664

Conditions

Haematological Malignancies

Interventions

AS703569

Study Description

Brief Summary: EMD Serono decided to terminate enrollment based on a review of the available clinical data and low probability of completing the trial based on the observed recruitment rate. Subjects already enrolled in the study continued participation in the study, consistent with the protocol, to study completion.

Detailed Description: The goal of this research study is to investigate for the first time the safety and tolerability of a new drug (AS703569), called an aurora kinase inhibitor, being tested to treat blood cancers in patients with different blood cancers. The research study will also assess how the body breaks down AS703569 and what changes occur in the blood after oral doses of AS703569. It will also look to see if there is any improvement in your blood cancer. The use of AS703569 in this study is experimental.